The Medicines Manufacturing Innovation Centre (MMIC), Monash University commenced a far reaching investigation into the myliquitab technology in March 2017.
MMIC has completed the first phase of their independent evaluation and characterization of the myLiquitab Homecare dispersion unit. The interim report provides evaluation of the myLiquitab system covering a range of representative tablets from granulated or direct compressed formulations.
- All tablets disintegrated within 4 minutes into a liquid dispersion using myLiquitab as per the provided patient instructions.
- Water heating from ultra-sonication of approximately 5°C was observed over the 4 minute time period, which is not considered a significant risk to chemical stability over the timescale involved in anticipated dosing.
- Dose delivery from the dispensed tablets was effective, with residual drug less than 1% of dose, resulting in greater than 99% of the drug dose delivered from the liquid dispersion.
- Particle size analysis indicated dispersions were suitable for delivery in each case.